{"id":8195,"date":"2026-07-08T14:28:48","date_gmt":"2026-07-08T11:28:48","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=8195"},"modified":"2026-07-08T21:29:27","modified_gmt":"2026-07-08T18:29:27","slug":"satellos-sat-3247-trailhead-duchenne-trial-results","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/satellos-sat-3247-trailhead-duchenne-trial-results\/","title":{"rendered":"SAT-3247 Alt\u0131 Ayl\u0131k Sonu\u00e7lar\u0131, Duchenne Kas Distrofisi Olan Yeti\u015fkinlerde Kas Ya\u011f\u0131nda Azalma ve CK D\u00fczeyinde D\u00fc\u015f\u00fc\u015f G\u00f6sterdi"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>TRAILHEAD klinik denemesinden elde edilen yeni alt\u0131 ayl\u0131k ara sonu\u00e7lar, SAT-3247&#039;nin Duchenne kas distrofisi (DMD) ile ya\u015fayan yeti\u015fkinlerde kas sa\u011fl\u0131\u011f\u0131n\u0131 iyile\u015ftirmeye ve fiziksel i\u015flevi korumaya yard\u0131mc\u0131 olabilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir.<\/strong> Deneysel tedavi, kas ya\u011f\u0131nda azalma, \u00fcst ekstremite performans\u0131nda iyile\u015fme, kas g\u00fcc\u00fcnde istikrar ve kas hasar\u0131yla ili\u015fkili bir biyomarker olan kreatin kinaz (CK) seviyelerinde d\u00fc\u015f\u00fc\u015f de dahil olmak \u00fczere bir\u00e7ok \u00f6nemli \u00f6l\u00e7\u00fcmde cesaret verici de\u011fi\u015fiklikler g\u00f6stermi\u015ftir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bulgular, daha \u00f6nce Faz 1a\/b CL-101 \u00e7al\u0131\u015fmas\u0131n\u0131 tamamlam\u0131\u015f ve devam eden TRAILHEAD uzatma \u00e7al\u0131\u015fmas\u0131nda tedavilerine devam eden 21 ila 28 ya\u015flar\u0131 aras\u0131ndaki d\u00f6rt yeti\u015fkinden elde edilmi\u015ftir.<\/strong> Kat\u0131l\u0131mc\u0131 say\u0131s\u0131 az olsa da, birden fazla sonu\u00e7 \u00f6l\u00e7\u00fct\u00fcnde elde edilen sonu\u00e7lar\u0131n tutarl\u0131l\u0131\u011f\u0131, SAT-3247&#039;nin alt\u0131 ayl\u0131k tedaviden sonra da biyolojik olarak aktif kald\u0131\u011f\u0131na dair cesaret verici kan\u0131tlar sunmaktad\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Genetik mutasyonlar\u0131 hedef alan bir\u00e7ok mevcut tedavinin aksine, SAT-3247 mutasyondan ba\u011f\u0131ms\u0131z bir tedavi olarak geli\u015ftiriliyor. Ara\u015ft\u0131rmac\u0131lar, bu tedavinin, \u015fu anda s\u0131n\u0131rl\u0131 tedavi se\u00e7eneklerine sahip yeti\u015fkinler de dahil olmak \u00fczere, Duchenne kas distrofisiyle ya\u015fayan geni\u015f bir insan grubuna fayda sa\u011flayabilece\u011fini umuyor.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#six-month-trailhead-results\">Alt\u0131 Ayl\u0131k TRAILHEAD Sonu\u00e7lar\u0131<\/a><\/li><li><a href=\"#mri-shows-reduced-muscle-fat\">MR g\u00f6r\u00fcnt\u00fclemesi kas ya\u011f\u0131nda azalma oldu\u011funu g\u00f6sterdi.<\/a><\/li><li><a href=\"#upper-limb-performance-improved\">\u00dcst Ekstremite Performans\u0131 Geli\u015ftirildi<\/a><\/li><li><a href=\"#muscle-strength-remained-stable\">Kas G\u00fcc\u00fc Sabit Kald\u0131<\/a><\/li><li><a href=\"#ck-levels-fell-by-38\">CK Seviyeleri 38% Azald\u0131<\/a><\/li><li><a href=\"#what-is-sat-3247\">SAT-3247 nedir?<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"six-month-trailhead-results\" class=\"wp-block-heading\">Alt\u0131 Ayl\u0131k TRAILHEAD Sonu\u00e7lar\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ara analiz, SAT-3247 ile alt\u0131 ayl\u0131k s\u00fcrekli tedavi sonras\u0131nda kas sa\u011fl\u0131\u011f\u0131, fiziksel performans ve g\u00fcvenlik gibi \u00e7e\u015fitli y\u00f6nleri de\u011ferlendirdi.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Satellos Bioscience&#039;ye g\u00f6re, d\u00f6rt kat\u0131l\u0131mc\u0131n\u0131n tamam\u0131nda \u00e7al\u0131\u015fma s\u00fcresince de\u011ferlendirilen temel klinik \u00f6l\u00e7\u00fcmlerde olumlu veya istikrarl\u0131 de\u011fi\u015fiklikler g\u00f6zlemlenmi\u015ftir. Bunlar \u015funlard\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>MRI ile \u00f6l\u00e7\u00fclen kas ya\u011f\u0131nda azalma<\/li>\n\n\n\n<li>\u00dcst ekstremite \u00e7abas\u0131nda iyile\u015fme<\/li>\n\n\n\n<li>\u0130stikrarl\u0131 kas g\u00fcc\u00fc<\/li>\n\n\n\n<li>Kreatin kinaz (CK) seviyelerinin d\u00fc\u015fmesi<\/li>\n\n\n\n<li>Ciddi tedaviyle ili\u015fkili yan etkilerin g\u00f6r\u00fclmemesiyle olumlu bir g\u00fcvenlik profili sunmaktad\u0131r.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Daha b\u00fcy\u00fck \u00f6l\u00e7ekli \u00e7al\u0131\u015fmalara ihtiya\u00e7 duyulsa da, Duchenne ara\u015ft\u0131rmalar\u0131nda yaln\u0131zca bir \u00f6l\u00e7\u00fcmde de\u011fil, birka\u00e7 farkl\u0131 \u00f6l\u00e7\u00fcmde iyile\u015fme g\u00f6r\u00fclmesi cesaret verici olarak kabul ediliyor. DMD&#039;li yeti\u015fkinlerde zaman i\u00e7inde s\u00fcrekli kas kayb\u0131 ve artan ya\u011f dokusu yenilenmesi ya\u015fan\u0131r; bu nedenle stabilizasyon ba\u015fl\u0131 ba\u015f\u0131na \u00f6nemli bir klinik hedeftir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"mri-shows-reduced-muscle-fat\" class=\"wp-block-heading\">MR g\u00f6r\u00fcnt\u00fclemesi kas ya\u011f\u0131nda azalma oldu\u011funu g\u00f6sterdi.<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En dikkat \u00e7ekici bulgulardan biri, manyetik rezonans g\u00f6r\u00fcnt\u00fcleme (MRI) kullan\u0131larak \u00f6l\u00e7\u00fclen kas ya\u011f oran\u0131ndaki azalmayd\u0131.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisinde kaslar hasar g\u00f6rd\u00fck\u00e7e, sa\u011fl\u0131kl\u0131 kas dokusu yava\u015f yava\u015f ya\u011f ve skar dokusuyla yer de\u011fi\u015ftirir. Bu s\u00fcre\u00e7 kas fonksiyonunu azalt\u0131r ve hastal\u0131\u011f\u0131n ilerlemesine katk\u0131da bulunur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Alt\u0131 ayl\u0131k tedavinin ard\u0131ndan:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>D\u00f6rt kat\u0131l\u0131mc\u0131n\u0131n tamam\u0131nda kas ya\u011f\u0131nda azalma g\u00f6r\u00fcld\u00fc.<\/li>\n\n\n\n<li><strong>Ortalama kas ya\u011f oran\u0131, ba\u015flang\u0131\u00e7taki 49,7% de\u011ferinden alt\u0131 ay sonra 46,0% de\u011ferine d\u00fc\u015ft\u00fc.<\/strong><\/li>\n\n\n\n<li>Bu, ortalama 3,7 puanl\u0131k bir iyile\u015fmeyi temsil etmektedir.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Ara\u015ft\u0131rmac\u0131lar, bu azalman\u0131n daha sa\u011fl\u0131kl\u0131 kas yap\u0131s\u0131na i\u015faret edebilece\u011fine inan\u0131yor. Daha fazla kat\u0131l\u0131mc\u0131yla yap\u0131lacak ek \u00e7al\u0131\u015fmalara ihtiya\u00e7 duyulsa da, ya\u011f birikiminin artmas\u0131 Duchenne hastal\u0131\u011f\u0131n\u0131n ilerlemesinin belirleyici \u00f6zelliklerinden biri oldu\u011fundan, ya\u011f yenilenmesinin yava\u015flat\u0131lmas\u0131 veya tersine \u00e7evrilmesi anlaml\u0131 bir hedef olarak kabul ediliyor.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"upper-limb-performance-improved\" class=\"wp-block-heading\">\u00dcst Ekstremite Performans\u0131 Geli\u015ftirildi<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7al\u0131\u015fmada ayr\u0131ca, SYSNAV Syde\u00ae giyilebilir sistemiyle toplanan bir \u00f6l\u00e7\u00fcm olan TE99C kullan\u0131larak \u00fcst ekstremite eforu da de\u011ferlendirildi. Bu teknoloji, kat\u0131l\u0131mc\u0131lar\u0131n g\u00fcnl\u00fck \u00fcst ekstremite hareketleri s\u0131ras\u0131nda ne kadar efor sarf ettiklerini \u00f6l\u00e7mektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Alt\u0131 ayl\u0131k tedavinin ard\u0131ndan:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>T\u00fcm kat\u0131l\u0131mc\u0131lar TE99C puanlar\u0131nda iyile\u015fme g\u00f6sterdi.<\/strong><\/li>\n\n\n\n<li>Ortalama performans, daha \u00f6nceki CL-101 \u00e7al\u0131\u015fmas\u0131nda 16,1 joule\/kg iken, TRAILHEAD \u00e7al\u0131\u015fmas\u0131nda alt\u0131 ay sonra 21,6 joule\/kg&#039;a y\u00fckselmi\u015ftir.<\/li>\n\n\n\n<li><strong>Bu, yakla\u015f\u0131k 34%&#039;lik ortalama bir iyile\u015fmeye kar\u015f\u0131l\u0131k gelir.<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Duchenne kas distrofisi ilerledik\u00e7e \u00fcst ekstremite fonksiyonu giderek daha \u00f6nemli hale gelir \u00e7\u00fcnk\u00fc bir\u00e7ok yeti\u015fkin g\u00fcnl\u00fck aktivitelerinde ba\u011f\u0131ms\u0131zl\u0131klar\u0131n\u0131 sa\u011flamak i\u00e7in sonunda kollar\u0131na ve ellerine ba\u011f\u0131ml\u0131 hale gelir. Bu nedenle, hareket \u00e7abas\u0131ndaki iyile\u015fmeler, daha b\u00fcy\u00fck klinik \u00e7al\u0131\u015fmalarda do\u011frulan\u0131rsa, anlaml\u0131 fonksiyonel faydalar sa\u011flayabilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"muscle-strength-remained-stable\" class=\"wp-block-heading\">Kas G\u00fcc\u00fc Sabit Kald\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Duchenne kas distrofisi ile ya\u015fayan yeti\u015fkinlerde kas g\u00fcc\u00fcn\u00fc korumak genellikle olumlu bir sonu\u00e7 olarak kabul edilir, \u00e7\u00fcnk\u00fc hastal\u0131k zamanla ilerleyici kas g\u00fc\u00e7s\u00fczl\u00fc\u011f\u00fcne neden olur.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ara\u015ft\u0131rmac\u0131lar, \u00fcst ekstremite kuvvetinin \u00e7e\u015fitli \u00f6l\u00e7\u00fcmlerini de\u011ferlendirdiler; bunlar aras\u0131nda \u015funlar yer almaktad\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>El kavrama g\u00fcc\u00fc<\/li>\n\n\n\n<li>Dirsek g\u00fcc\u00fc<\/li>\n\n\n\n<li>Omuz g\u00fcc\u00fc<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00f6l\u00e7\u00fcmler boyunca, kat\u0131l\u0131mc\u0131lar\u0131n genel performans\u0131 alt\u0131 ayl\u0131k tedavi s\u00fcresi boyunca istikrarl\u0131 kald\u0131. \u00d6zellikle, daha \u00f6nceki 28 g\u00fcnl\u00fck CL-101 \u00e7al\u0131\u015fmas\u0131nda g\u00f6zlemlenen el kavrama g\u00fcc\u00fcndeki yakla\u015f\u0131k iki katl\u0131k iyile\u015fme, TRAILHEAD uzatma \u00e7al\u0131\u015fmas\u0131 s\u0131ras\u0131nda da korundu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TRAILHEAD&#039;ye girdikten sonra g\u00fc\u00e7te \u00f6nemli bir art\u0131\u015f bildirilmemi\u015f olsa da, Duchenne gibi ilerleyici bir hastal\u0131kta alt\u0131 ay boyunca \u00f6nceki iyile\u015fmelerin korunmas\u0131 klinik a\u00e7\u0131dan anlaml\u0131 olabilir.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"ck-levels-fell-by-38\" class=\"wp-block-heading\">CK Seviyeleri 38% Azald\u0131<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bir di\u011fer cesaret verici bulgu ise kas hasar\u0131n\u0131n \u00f6nemli bir biyobelirteci olan kreatin kinaz (CK) ile ilgiliydi.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">CK, kas lifleri hasar g\u00f6rd\u00fc\u011f\u00fcnde kan dola\u015f\u0131m\u0131na sal\u0131nan bir enzimdir. Duchenne kas distrofisi olan ki\u015filerde, kaslar\u0131 s\u00fcrekli olarak hasar g\u00f6rd\u00fc\u011f\u00fc i\u00e7in CK seviyeleri genellikle \u00e7ok y\u00fcksektir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7al\u0131\u015fma s\u00fcresince:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>CL-101 \u00e7al\u0131\u015fmas\u0131n\u0131n ba\u015flang\u0131c\u0131nda ortalama CK seviyeleri 2.130 U\/L iken, TRAILHEAD \u00e7al\u0131\u015fmas\u0131nda alt\u0131 ay sonra 1.315 U\/L&#039;ye d\u00fc\u015ft\u00fc.<\/li>\n\n\n\n<li><strong>Bu, ortalama 38%&#039;lik bir azalmay\u0131 temsil etmektedir.<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00fc\u015f\u00fck CK seviyeleri, devam eden kas hasar\u0131n\u0131n azald\u0131\u011f\u0131n\u0131 g\u00f6sterebilir. Bununla birlikte, ara\u015ft\u0131rmac\u0131lar genellikle CK&#039;y\u0131 tek ba\u015f\u0131na bir tedavi etkinli\u011fi g\u00f6stergesi olarak de\u011fil, fonksiyonel de\u011ferlendirmeler ve g\u00f6r\u00fcnt\u00fcleme sonu\u00e7lar\u0131yla birlikte yorumlarlar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/s203.q4cdn.com\/439234936\/files\/doc_presentation\/2026\/07\/Satellos_Corporate_Deck_7-8-26.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Hepsi hakk\u0131nda daha fazla bilgi edinin.<\/a><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 id=\"what-is-sat-3247\" class=\"wp-block-heading\">SAT-3247 nedir?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>SAT-3247, Duchenne kas distrofisi olan ki\u015filer i\u00e7in Satellos Bioscience taraf\u0131ndan geli\u015ftirilen deneysel bir tedavidir. Halen klinik \u00e7al\u0131\u015fmalarda incelenmekte olup, rutin t\u0131bbi kullan\u0131m i\u00e7in onaylanmam\u0131\u015ft\u0131r.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-video is-provider-vimeo wp-block-embed-vimeo wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Satellos: SAT-3247 Etki Mekanizmas\u0131\" src=\"https:\/\/player.vimeo.com\/video\/1111725853?dnt=1&amp;app_id=122963\" width=\"696\" height=\"392\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture; clipboard-write; encrypted-media; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gen terapileri veya ekzon atlama tedavilerinin aksine, SAT-3247, distrofin genini de\u011fi\u015ftirmeyi veya distrofin \u00fcretimini geri kazand\u0131rmay\u0131 hedeflemez. Bunun yerine, v\u00fccudun do\u011fal kas onar\u0131m s\u00fcrecini desteklemek \u00fczere tasarlanm\u0131\u015ft\u0131r.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Bu terapi, uydu h\u00fccreleri olarak da bilinen kas k\u00f6k h\u00fccrelerine odaklanmaktad\u0131r. Bu h\u00fccreler, ya\u015fam boyunca hasar g\u00f6rm\u00fc\u015f kas liflerinin onar\u0131m\u0131nda kritik bir rol oynar. Duchenne kas distrofisinde, tekrarlayan kas hasar\u0131 d\u00f6ng\u00fcleri, bu k\u00f6k h\u00fccrelerin sa\u011fl\u0131kl\u0131 kas dokusunu yenileme yetene\u011fini kademeli olarak azalt\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SAT-3247, bu kas k\u00f6k h\u00fccrelerinin b\u00f6l\u00fcnmesine ve kas onar\u0131m\u0131na daha etkili bir \u015fekilde yard\u0131mc\u0131 olmak \u00fczere tasarlanm\u0131\u015ft\u0131r. Ara\u015ft\u0131rmac\u0131lar, kas\u0131n do\u011fal yenilenme kapasitesini art\u0131rarak, bu tedavinin hastal\u0131k ilerlemesini yava\u015flatabilece\u011fini ve zaman i\u00e7inde kas fonksiyonunu koruyabilece\u011fini umuyorlar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mekanizmas\u0131 belirli bir distrofin mutasyonuna ba\u011fl\u0131 olmad\u0131\u011f\u0131 i\u00e7in, SAT-3247, Duchenne kas distrofisi olan geni\u015f bir hasta yelpazesinde kullan\u0131lma potansiyeline sahiptir. Bu mutasyondan ba\u011f\u0131ms\u0131z yakla\u015f\u0131m, gelecekteki klinik \u00e7al\u0131\u015fmalar g\u00fcvenli\u011fini ve etkinli\u011fini g\u00f6stermeye devam ederse, hem ayakta tedavi g\u00f6ren hem de ayakta tedavi g\u00f6rmeyen hastalar i\u00e7in uygun hale getirebilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu Sayfay\u0131 Takip Edin<\/strong>&nbsp;&gt;&gt;&gt; <a href=\"https:\/\/dmdwarrior.com\/tr\/clinical-trials\/\">Duchenne Klinik Ara\u015ft\u0131rmalar\u0131n\u0131 Ke\u015ffedin<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>New six-month interim results from the TRAILHEAD clinical trial suggest that SAT-3247 may help improve muscle health and preserve physical function in adults living with Duchenne muscular dystrophy (DMD). The investigational treatment demonstrated encouraging changes in several important measures, including reduced muscle fat, improved upper limb effort, stable muscle strength, and lower levels of creatine [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8199,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[251,252,253,259,829],"class_list":["post-8195","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-sat-3247","tag-satellos","tag-satellos-bioscience","tag-stem-cell-therapy","tag-trailhead"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=8195"}],"version-history":[{"count":6,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8195\/revisions"}],"predecessor-version":[{"id":8204,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/8195\/revisions\/8204"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/8199"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=8195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=8195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=8195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}